Multiple Sclerosis Disease-Modifying Treatment Algorithms: 2025 Positioning of the Portuguese Multiple Sclerosis Study Group
DOI:
https://doi.org/10.20344/amp.22380Keywords:
Age of Onset, Multiple Sclerosis/drug therapy, Multiple Sclerosis, Relapsing-Remitting/drug therapyAbstract
Multiple sclerosis (MS) is a chronic autoimmune-mediated neurodegenerative disease characterized by inflammation, demyelination, and axonal/neuronal damage in the central nervous system. In Portugal, the prevalence of MS is approximately 64.4 per 100 000 individuals. It is typically diagnosed in young adults aged 30 to 40, with a higher incidence in women, although it can also affect children/adolescents and the elderly. Recent advances in MS treatment include the development and approval of several new disease-modifying therapies (DMTs) such as ocrelizumab, cladribine, siponimod, and others, thus expanding options for relapsing-remitting MS (RRMS). However, the options for progressive forms of MS remain limited. In Portugal, MS management strategies, guided by the 2015 recommendations of the Directorate-General of Health and the Portuguese medicines agency, need updating to incorporate recent scientific evidence and clinical expertise. The aim of this manuscript is to highlight gaps in current Portuguese MS treatment algorithms and propose enhancements aligned with global standards, thus improving treatment selection and patient outcomes in the Portuguese healthcare system. Developed by nine Portuguese neurology experts from the Portuguese Multiple Sclerosis Study Group, this document not only provides evidence and clinical practice-based recommendations but also includes DMT algorithms tailored for various MS subtypes, including radiologically and clinically isolated syndromes, RRMS, progressive MS, and specific situations in MS treatment such as pediatric-onset MS, late-onset MS, pregnancy and breastfeeding. This document provides evidence- and clinical practice-based recommendations to optimize decision-making during MS management in Portuguese centers. The experts aim to prompt the urgent revision of national MS treatment frameworks, incorporating the latest advancements in MS research and international guidelines, to reduce the socio-economic burden on the national healthcare system and improve the long-term health outcomes of MS patients.
Downloads
References
Shah A, Panchal V, Patel K, Alimohamed Z, Kaka N, Sethi Y, et al. Pathogenesis and management of multiple sclerosis revisited. Dis Mon. Sep 2023;69:101497. DOI: https://doi.org/10.1016/j.disamonth.2022.101497
Branco M, Alves I, Martins da Silva A, Pinheiro J, Sa MJ, Correia I, et al. The epidemiology of multiple sclerosis in the entre Douro e Vouga region of northern Portugal: a multisource population-based study. BMC Neurol. 2020;20:195. DOI: https://doi.org/10.1186/s12883-020-01755-8
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26:1816-21. DOI: https://doi.org/10.1177/1352458520970841
Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. The increased susceptibility of women to multiple sclerosis. Can J Neurol Sci. 1992;19:466-71. DOI: https://doi.org/10.1017/S0317167100041664
Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378:169-80. DOI: https://doi.org/10.1056/NEJMra1401483
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162-73. DOI: https://doi.org/10.1016/S1474-4422(17)30470-2
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278-86. DOI: https://doi.org/10.1212/WNL.0000000000000560
Lublin FD, Haring DA, Ganjgahi H, Ocampo A, Hatami F, Cuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145:3147-61. DOI: https://doi.org/10.1093/brain/awac016
De Stefano N, Giorgio A, Tintore M, Pia Amato M, Kappos L, Palace J, et al. Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Mult Scler. 2018;24:214-21. DOI: https://doi.org/10.1177/1352458517717808
Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009;72:800-5. DOI: https://doi.org/10.1212/01.wnl.0000335764.14513.1a
Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287-300. DOI: https://doi.org/10.1038/s41582-019-0170-8
Bergamaschi R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol. 2007;79:423-47. DOI: https://doi.org/10.1016/S0074-7742(07)79019-0
Vasconcelos CC, Aurencao JC, Thuler LC, Camargo S, Alvarenga MP, Alvarenga RM. Prognostic factors associated with long-term disability and secondary progression in patients with Multiple Sclerosis. Mult Scler Relat Disord. 2016;8:27-34. DOI: https://doi.org/10.1016/j.msard.2016.03.011
Vidal-Jordana A, Montalban X. Multiple Sclerosis: epidemiologic, clinical, and therapeutic aspects. Neuroimaging Clin N Am. 2017;27:195-204. DOI: https://doi.org/10.1016/j.nic.2016.12.001
Amin M, Hersh CM. Updates and advances in multiple sclerosis neurotherapeutics. Neurodegener Dis Manag. 2023;13:47-70. DOI: https://doi.org/10.2217/nmt-2021-0058
Freedman MS, Devonshire V, Duquette P, Giacomini PS, Giuliani F, Levin MC, et al. Treatment optimization in multiple sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci. 2020;47:437-55. DOI: https://doi.org/10.1017/cjn.2020.66
Gold R, Wolinsky JS, Amato MP, Comi G. Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord. 2010;3:351-67. DOI: https://doi.org/10.1177/1756285610385608
Giovannoni G, Tomic D, Bright JR, Havrdova E. “No evident disease activity”: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23:1179-87. DOI: https://doi.org/10.1177/1352458517703193
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, et al. The CELLO trial: protocol of a planned phase 4 study to assess the efficacy of ocrelizumab in patients with radiologically isolated syndrome. Mult Scler Relat Disord. 2022;68:104143. DOI: https://doi.org/10.1016/j.msard.2022.104143
Lebrun-Frenay C, Kantarci O, Siva A, Sormani MP, Pelletier D, Okuda DT, et al. Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Ann Neurol. 2020;88:407-17. DOI: https://doi.org/10.1002/ana.25799
Lebrun-Frenay C, Siva A, Sormani MP, Landes-Chateau C, Mondot L, Bovis F, et al. Teriflunomide and time to clinical multiple sclerosis in patients with radiologically isolated syndrome: the TERIS randomized clinical Trial. JAMA Neurol. 2023;80:1080-8. DOI: https://doi.org/10.1001/jamaneurol.2023.2815
Okuda DT, Kantarci O, Lebrun-Frenay C, Sormani MP, Azevedo CJ, Bovis F, et al. Dimethyl fumarate delays multiple sclerosis in radiologically isolated syndrome. Ann Neurol. 2023;93:604-14. DOI: https://doi.org/10.1002/ana.26555
Sanofi. Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in nonrelapsing secondary progressive multiple sclerosis. 2024. [cited 2024 Sept 11]. Available from: https://www.sanofi.com/en/media-room/press-releas es/2024/2024-09-02-05-00-00-2938875.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, et al. Inhibition of CD40L with frexalimab in multiple sclerosis. N Engl J Med. 2024;390:589-600. DOI: https://doi.org/10.1056/NEJMoa2309439
Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology. 2010;74:1822-6. DOI: https://doi.org/10.1212/WNL.0b013e3181e0f7e6
Direção-Geral da Saúde. Norma n.º 005/2012 de 04/12/2012 atualizada a 31/07/2015. Terapêutica modificadora da esclerose múltipla em idade pediátrica e no adulto. 2015. [cited 2024 Jan 17]. Available from: https://normas.dgs.min-saude.pt/2012/12/04/terapeutica-modificadora-da-esclerosemultipla- na-idade-pediatrica-e-no-adulto/.
Comissão Nacional de Farmácia e Terapêutica. Orientações - utilização de fármacos para o tratamento da esclerose múltipla. 2023. [cited 2024 Jan 17]. Available from: https://www.infarmed.pt/documents/15786/1816213/Utiliza%C3%A7%C3%A3o+de+f%C3%A1rmacos+para+o+tratamento+da+esclero se+m%C3%BAltipla/0258cf4d-3e9e-8484-4200-2d06d6c699ec?version=1.0.
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96-120. DOI: https://doi.org/10.1177/1352458517751049
Yamout B, Al-Jumah M, Sahraian MA, Almalik Y, Khaburi JA, Shalaby N, et al. Consensus recommendations for diagnosis and treatment of multiple sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord. 2024;83:105435. DOI: https://doi.org/10.1016/j.msard.2024.105435
Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BA, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90:777-88. DOI: https://doi.org/10.1212/WNL.0000000000005347
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Maurer M, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on diseasemodifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021;14:17562864211039648. DOI: https://doi.org/10.1177/17562864211039648
National Health Service England. Treatment Algorithm for Multiple Sclerosis Disease-Modifying Therapies 2023. [cited 2024 Feb 02]. Available from: https://www.england.nhs.uk/wp-content/uploads/2024/03/treatment-algorithm-for-multiple-sclerosis-disease-modifying-therapies-july-23.pdf.
Meca-Lallana JE, Martinez Yelamos S, Eichau S, Llaneza MA, Martin Martinez J, Pena Martinez J, et al. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023. Neurologia. 2024;39:196-208. DOI: https://doi.org/10.1016/j.nrleng.2024.01.003
Comissão Nacional de Farmácia e Terapêutica. Orientações - utilização de fármacos para o tratamento da esclerose múltipla. 2019. [cited 2024 Jan 17]. Note: the document has since been updated (see reference 27) and the version originally accessed is no longer available online.
Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269:5382-94. DOI: https://doi.org/10.1007/s00415-022-11193-w
Filippi M, Danesi R, Derfuss T, Duddy M, Gallo P, Gold R, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269:1670-7. DOI: https://doi.org/10.1007/s00415-021-10836-8
Brown JW, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321:175-87. DOI: https://doi.org/10.1001/jama.2018.20588
Buron MD, Chalmer TA, Sellebjerg F, Barzinji I, Danny B, Christensen JR, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95:e1041-51. DOI: https://doi.org/10.1212/WNL.0000000000010135
Hänninen K, Viitala M, Atula S, Laakso SM, Kuusisto H, Soilu-Hänninen M. Initial treatment strategy and clinical outcomes in Finnish MS patients: a propensity-matched study. J Neurol. 2021;269:913-22. DOI: https://doi.org/10.1007/s00415-021-10673-9
Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536-41. DOI: https://doi.org/10.1001/jamaneurol.2018.4905
Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78:1197-204. DOI: https://doi.org/10.1001/jamaneurol.2021.2738
Uher T, Krasensky J, Malpas C, Bergsland N, Dwyer MG, Kubala Havrdova E, et al. Evolution of brain volume loss rates in early stages of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8:e979. DOI: https://doi.org/10.1212/NXI.0000000000000979
Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16:658-65. DOI: https://doi.org/10.1016/j.autrev.2017.04.010
He A, Merkel B, Brown JW, Zhovits Ryerson L, Kister I, Malpas CB, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307-16. DOI: https://doi.org/10.1016/S1474-4422(20)30067-3
Simonsen CS, Flemmen HO, Broch L, Brunborg C, Berg-Hansen P, Moen SM, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front Neurol. 2021;12:693017. DOI: https://doi.org/10.3389/fneur.2021.693017
Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol. 2012;11:157-69. DOI: https://doi.org/10.1016/S1474-4422(11)70274-5
Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977-86. DOI: https://doi.org/10.1016/S1474-4422(14)70191-7
Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13:257-67. DOI: https://doi.org/10.1016/S1474-4422(14)70005-5
Kappos L, Bar-Or A, Cree BA, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263-73. DOI: https://doi.org/10.1016/S0140-6736(18)30475-6
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209-20. DOI: https://doi.org/10.1056/NEJMoa1606468
Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460-71. DOI: https://doi.org/10.1002/ana.21867
Hauser SL, Bar-Or A, Weber MS, Kletzl H, Gunther A, Manfrini M, et al. Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10:e200094. DOI: https://doi.org/10.1212/NXI.0000000000200094
Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S, et al. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022;93:1330-7. DOI: https://doi.org/10.1136/jnnp-2022-330104
Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B. Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol. 2014;13:936-48. DOI: https://doi.org/10.1016/S1474-4422(14)70093-6
Silva A, Sá M. Esclerosis múltiple de inicio juvenil. Rev Neurol. 1999;28:1036-40. DOI: https://doi.org/10.33588/rn.2811.99064
Correia AS, Augusto L, Meireles J, Pinto J, Sousa AP. Pediatric multiple sclerosis in Portugal: a multicentre study. Acta Med Port. 2016;29:425-31. DOI: https://doi.org/10.20344/amp.6346
Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356:2603-13. DOI: https://doi.org/10.1056/NEJMoa067597
Banwell B, Kennedy J, Sadovnick D, Arnold DL, Magalhaes S, Wambera K, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology. 2009;72:232-9. DOI: https://doi.org/10.1212/01.wnl.0000339482.84392.bd
Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler. 2012;18:116-27. DOI: https://doi.org/10.1177/1352458511430704
Banwell B, Reder AT, Krupp L, Tenembaum S, Eraksoy M, Alexey B, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology. 2006;66:472-6. DOI: https://doi.org/10.1212/01.wnl.0000198257.52512.1a
Gartner J, Bruck W, Weddige A, Hummel H, Norenberg C, Bugge JP, et al. Interferon beta-1b in treatment-naive paediatric patients with relapsingremitting multiple sclerosis: two-year results from the BETAPAEDIC study. Mult Scler J Exp Transl Clin. 2017;3:2055217317747623. DOI: https://doi.org/10.1177/2055217317747623
Ghezzi A, Amato MP, Capobianco M, Gallo P, Marrosu MG, Martinelli V, et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta- 1a: long-term results. Neurol Sci. 2007;28:127-32. DOI: https://doi.org/10.1007/s10072-007-0804-2
Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology. 2005;64:888-90. DOI: https://doi.org/10.1212/01.WNL.0000153570.33845.6A
Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, et al. Subcutaneous interferon beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol. 2013;28:849-56. DOI: https://doi.org/10.1177/0883073813488828
Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci. 2009;30:193-9. DOI: https://doi.org/10.1007/s10072-009-0083-1
Chitnis T, Banwell B, Kappos L, Arnold DL, Gucuyener K, Deiva K, et al. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021;20:1001-11. DOI: https://doi.org/10.1016/S1474-4422(21)00364-1
Chitnis T, Arnold DL, Banwell B, Bruck W, Ghezzi A, Giovannoni G, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379:1017-27. DOI: https://doi.org/10.1056/NEJMoa1800149
Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS). Pediatr Neurol. 2018;83:19-24. DOI: https://doi.org/10.1016/j.pediatrneurol.2018.03.007
Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M, Blaschek A, Valis M, Aaen G, et al. Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsing-remitting multiple sclerosis. Front Neurol. 2020;11:606418. DOI: https://doi.org/10.3389/fneur.2020.606418
Hacohen Y, Banwell B, Ciccarelli O. What does first-line therapy mean for paediatric multiple sclerosis in the current era? Mult Scler. 2021;27:1970-6. DOI: https://doi.org/10.1177/1352458520937644
Etemadifar M, Nouri H, Sedaghat N, Ramezani A, Kargaran PK, Salari M, et al. Anti-CD20 therapies for pediatric-onset multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2024;91:105849. DOI: https://doi.org/10.1016/j.msard.2024.105849
Margoni M, Rinaldi F, Miante S, Franciotta S, Perini P, Gallo P. Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis. Mult Scler J Exp Transl Clin. 2019;5:2055217319875471. DOI: https://doi.org/10.1177/2055217319875471
Palavra F, Figueiroa S, Correia AS, Tapadinhas F, Cerqueira J, Guerreiro RP, et al. TyPed study: natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal. Mult Scler Relat Disord. 2021;51:102865. DOI: https://doi.org/10.1016/j.msard.2021.102865
Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369-74. DOI: https://doi.org/10.1056/NEJMoa051782
Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353:362-8. DOI: https://doi.org/10.1056/NEJMoa051586
Polliack ML, Barak Y, Achiron A. Late-onset multiple sclerosis. J Am Geriatr Soc. 2001;49:168-71. DOI: https://doi.org/10.1046/j.1532-5415.2001.49038.x
Roohani P, Emiru T, Carpenter A, Luzzio C, Freeman J, Scarberry S, et al. Late onset multiple sclerosis: is it really late onset? Mult Scler Relat Disord. 2014;3:444-9. DOI: https://doi.org/10.1016/j.msard.2014.02.004
Naseri A, Nasiri E, Sahraian MA, Daneshvar S, Talebi M. Clinical features of late-onset multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021;50:102816. DOI: https://doi.org/10.1016/j.msard.2021.102816
Moura J, Duarte S, Oliveira V, Pereira D, Costa D, Samoes R, et al. Characterization of a late-onset multiple sclerosis Portuguese cohort. Mult Scler Relat Disord. 2023;70:104506. DOI: https://doi.org/10.1016/j.msard.2023.104506
Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577. DOI: https://doi.org/10.3389/fneur.2017.00577
Buscarinu MC, Renie R, Morena E, Romano C, Bellucci G, Marrone A, et al. Late-onset MS: disease course and safety-efficacy of DMTS. Front Neurol. 2022;13:829331. DOI: https://doi.org/10.3389/fneur.2022.829331
Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, et al. Alemtuzumab outcomes by age: post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord. 2021;49:102717. DOI: https://doi.org/10.1016/j.msard.2020.102717
Devonshire V, Havrdova E, Radue EW, O’Connor P, Zhang-Auberson L, Agoropoulou C, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol. 2012;11:420- 8. DOI: https://doi.org/10.1016/S1474-4422(12)70056-X
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, et al. Efficacy of siponimod in secondary progressive multiple sclerosis: results of the phase 3 study (CT.002). Neurology. 2017;88. DOI: https://doi.org/10.1212/WNL.88.16_supplement.CT.002
Patti F, Penaherrera JN, Zieger L, Wicklein EM. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: posthoc analysis of a 2-year, prospective, international, observational study. BMC Neurol. 2021;21:324. DOI: https://doi.org/10.1186/s12883-021-02347-w
Shirani A, Zhao Y, Petkau J, Gustafson P, Karim ME, Evans C, et al. Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment. Biomed Res Int. 2015;2015:451912. DOI: https://doi.org/10.1155/2015/451912
Jesus-Ribeiro J, Correia I, Martins AI, Fonseca M, Marques I, Batista S, et al. Pregnancy in multiple sclerosis: a portuguese cohort study. Mult Scler Relat Disord. 2017;17:63-8. DOI: https://doi.org/10.1016/j.msard.2017.07.002
Novo A, Castelo J, de Sousa A, Amorim I, Alves JN, Calejo M, et al. Pregnancy outcomes in Portuguese women with multiple sclerosis: The PREGNIMS study. Mult Scler Relat Disord. 2019;28:172-6. DOI: https://doi.org/10.1016/j.msard.2018.12.033
Batista S, Martins da Silva A, Sá MJ, Sousa L, De Sá J, Pedrosa R, et al. Recomendações sobre a abordagem da esclerose múltipla na gravidez, parto e pós-parto: posição de consenso do Grupo de Estudos de Esclerose Múltipla. Acta Med Port. 2020;33:611-21. DOI: https://doi.org/10.20344/amp.12777
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022;21:608-19. DOI: https://doi.org/10.1016/S1474-4422(22)00143-0
Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19:106-14. DOI: https://doi.org/10.1136/practneurol-2018-002060
Varyte G, Arlauskiene A, Ramasauskaite D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021;33:378-83. DOI: https://doi.org/10.1097/GCO.0000000000000731
D’Amico E, Haase R, Ziemssen T. Review: patient-reported outcomes in multiple sclerosis care. Mult Scler Relat Disord. 2019;33:61-6. DOI: https://doi.org/10.1016/j.msard.2019.05.019
Sastre-Garriga J, Pareto D, Battaglini M, Rocca MA, Ciccarelli O, Enzinger C, et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol. 2020;16:171-82. DOI: https://doi.org/10.1038/s41582-020-0314-x
Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol. 2006;180:17-28. DOI: https://doi.org/10.1016/j.jneuroim.2006.07.006
Cross AH, Gelfand JM, Thebault S, Bennett JL, von Budingen HC, Cameron B, et al. Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis. JAMA Neurol. 2024;81:373-83. DOI: https://doi.org/10.1001/jamaneurol.2024.0017
Krysko KM, Dobson R, Alroughani R, Amato MP, Bove R, Ciplea AI, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350-66. DOI: https://doi.org/10.1016/S1474-4422(22)00426-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
